Biotech entity
acquisition is the sole category represented across all 1 tracked stories. Chrome Holding is most often covered alongside 23andMe, which appears in 1 of these 1 story. Chrome Holding appears in 1 tracked Biotech story from July 8, 2026. The tracked stories average 1 original source each.
Last mentioned: Jul 8, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
acquisition is the sole category represented across all 1 tracked stories. Chrome Holding is most often covered alongside 23andMe, which appears in 1 of these 1 story. Chrome Holding appears in 1 tracked Biotech story from July 8, 2026. The tracked stories average 1 original source each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Chrome Holding. Shared-story counts are live from our verified record — not editorial picks.
For the biotech world, the 23andMe saga is a stark lesson: acquiring assets out of bankruptcy does not shield from inherited data-breach liabilities. Anne Wojcicki’s $305 million purchase now carries a $46.75 million settlement that could chill future investments in consumer genomics.
Source: Kali Hays (gb)
Chrome Holding is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
